Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma

Zhang, Qianyun; Xiao, Qin; Lin, Zhen; Ying, Xiaohua; Li, Zhenjia; Lin, Jin‐Ming

doi:10.1016/j.clinbiochem.2010.04.074

Cited by 35 publications

(29 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven studies reported the diagnostic accuracy of serum GPC3 for early HCC (22,26,28,31,32,35,36), and four of the included studies investigated the diagnostic value of AFP (22,26,28,31). DOR and the pooled sensitivity for GPC3 were more elevated than AFP, and three of these studies clearly showed that GPC3 elevated diagnostic sensitivity for early HCC.…”

Section: Discussionmentioning

confidence: 94%

“…Finally, 19 studies were included in this metaanalysis, which recruited 3420 patients consisting of 1935 HCC patients and 1485 non-HCC patients who received serum GPC3 test (12,22e39). Eight studies recruited 982 patients who received both serum GPC3 and AFP tests (22,24,26,27,30,31,33,35), and seven studies recruited 756 patients investigating the diagnostic accuracy of serum GPC3 for early HCC (22,26,28,31,32,35,36). The characteristics of each study are shown in Table 1.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 97%

“…Seven studies (22,26,28,31,32,35,36) reported the diagnostic accuracy 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 of serum GPC3 and four studies (22,26,…”

Section: Summary Diagnostic Accuracy Of Serum Gpc3 and Afp For Early Hccunclassified

See 2 more Smart Citations

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Jia

Liu

Gao

et al. 2014

Archives of Medical Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 94%

Section: Characteristics Of Included Studiesmentioning

confidence: 97%

Section: Summary Diagnostic Accuracy Of Serum Gpc3 and Afp For Early Hccunclassified

See 1 more Smart Citation

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Jia

Liu

Gao

et al. 2014

Archives of Medical Research

View full text Add to dashboard Cite

“…8 Since then, several subsequent studies have found elevated serum GPC3 levels in patients with HCC and a lack of correlation with AFP. [9][10][11][12] However, the diagnostic value of serum GPC3 remains controversial, especially when compared to AFP. After analyzing data of 200 patients with HCC and 200 patients with chronic liver diseases, Yasuda et al found no elevation in serum GPC3 levels in patients with HCC in comparison to those with chronic liver disease, indicating that there was no clinical utility of serum GPC3 in the diagnosis of HCC.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma

Jia

Gao

Zhai

et al. 2016

Technol Cancer Res Treat

View full text Add to dashboard Cite

Glypican-3 has been reported to be one of the most promising serum markers for hepatocellular carcinoma. This study aimed to assess the clinical utility of serum glypican 3 for the diagnosis of hepatocellular carcinoma. We recruited consecutive patients on a large scale, 283 with hepatocellular carcinoma, 445 with chronic hepatic diseases, and 162 normal controls, to assess the diagnostic accuracy of serum glypican 3 for hepatocellular carcinoma by enzyme-linked immunosorbent assay. In addition, we further analyzed the relationship between the serum levels of a-fetoprotein and glypican-3 in patients with hepatocellular carcinoma. The results indicated that serum glypican 3 was elevated in patients with hepatocellular carcinoma (0 ng/mL, range ¼ 0-14.0 ng/mL, P ¼ .033) and liver cirrhosis (0 ng/mL, range ¼ 0-12.5 ng/mL, P ¼ .001) compared to the levels in normal control (0 ng/mL, range ¼ 0-4.3 ng/mL), but there was no difference between hepatocellular carcinoma and liver cirrhosis (P ¼ .097). The area under the curve of the receiver-operating characteristics curve for hepatocellular carcinoma versus all controls was 0.519, with a sensitivity of 39.9%, a specificity of 60.6%, and an optimal cutoff value of 0.002 ng/mL. The positive and negative predictive values were 32.0% and 68.3%, respectively. No significant correlation in serum levels was observed between glypican 3 and a-fetoprotein (P > .05). The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with a-fetoprotein. Glypican 3 was not a promising serum maker for the diagnosis of hepatocellular carcinoma alone, but it could be complementary to a-fetoprotein and elevate the sensitivity of hepatocellular carcinoma diagnosis.

show abstract

“…Several methods have been developed for the detection of serum GPC3, such as ELISA, competitive radioimmunoassay and chemiluminescent immunoassay, however, all these kits are still remained for research use only. The level of serum GPC3 ranges from 924.8 pg/mL to several hundreds of ng/mL in HCC patients using different methods [13,14]. Yasuda et al even found it didn't work well to diagnose HCC using a commercial ELISA kit with GPC3 antibody 1G12 [15].…”

Section: Introductionmentioning

confidence: 98%

Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3

et al. 2017

View full text Add to dashboard Cite

Glypican-3(GPC3), an oncofetal protein, is a potential novel marker for hepatocellular carcinoma (HCC). In this study, we attempted to establish a new method to detect serum GPC3 using the antibodies identified in our previous research, and then evaluated its clinical application for the diagnosis of HCC. Herein, a sandwich time-resolved fluorescence immunoassay (TRFIA) for detecting serum GPC3 was developed. The detection limit, analytical recovery, specificity and precision of the proposed TRFIA assay were satisfactory. A total of 415 patients were collected and divided into seven groups: hepatocellular carcinoma (101), colorectal cancer (67), gastric cancer (44), esophageal cancer (15), cirrhosis (55), hepatitis (61), normal liver (72). Using this proposed method, the concentration of serum GPC3 in these clinical samples was detected. The results demonstrated that the levels of GPC3 in serum from HCC patients were significantly higher than that in others. Compared with the results of chemiluminescence immunoassay (CLIA), a high consistency (Kappa =0.84) was observed. Thus, an effective, sensitive and reliable TRFIA-GPC3 kit for diagnosing HCC was successfully developed. It offers a suitable alternative to existed methods of determining GPC3 and is expected to be used in clinic in the future.

show abstract

Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma

Cited by 35 publications

References 29 publications

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma

Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3

Contact Info

Product

Resources

About